Cell Viability Assays and Consumables: Global Markets
REPORT SCOPE:
The scope of this report is broad and covers various types of products available in the cell viability assays market and potential application sectors in various industries. The cell viability assays market is broken down by product into instruments and consumables. Revenue forecasts from 2018 to 2023 are given for each product, application, cell type and end user, with estimated valued derived from the revenues of manufacturers. Revenue generated from the installation and maintenance of instruments has been excluded from the report.
The report also includes a discussion of the major players in each regional cell viability assays market. Further, it explains the major drivers and regional dynamics of the global market and current trends within the industry.
The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major players in the global cell viability assays market.
REPORT INCLUDES:
The scope of this report is broad and covers various types of products available in the cell viability assays market and potential application sectors in various industries. The cell viability assays market is broken down by product into instruments and consumables. Revenue forecasts from 2018 to 2023 are given for each product, application, cell type and end user, with estimated valued derived from the revenues of manufacturers. Revenue generated from the installation and maintenance of instruments has been excluded from the report.
The report also includes a discussion of the major players in each regional cell viability assays market. Further, it explains the major drivers and regional dynamics of the global market and current trends within the industry.
The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major players in the global cell viability assays market.
REPORT INCLUDES:
- 95 data tables and 66 additional tables
- An overview of the global cell viability assays market
- Analyses of global market trends, with data from 2017, 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Information on various type of products available in the cell viability assays market and potential applications across various industries
- Examination of the main product applications and markets in an effort to help companies and investors prioritize product opportunities and strategic movements
- Evaluation of key industry and market trends, and quantification of the main market segments, allowing the reader to better understand the industry’s structure and changes occurring within it
- Coverage of innovations and development in stem cell research, toxicity testing and tissue engineering
- Insight into regulatory framework and investment analysis in the healthcare sector
- Detailed profiles of the major players of the industry, including Bio-Rad Laboratories Inc., Danaher Corp., GE Healthcare, Merck KGaA and R&D Systems Inc.
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET OVERVIEW
Introduction
Market Potential
Market Size and Growth
Consumer Types and Product Success
Competitor Pricing
Regulatory Framework
United States
European Union
China
India
Japan
Australia
Brazil
Russia
Investment Analysis
Industry Growth Drivers
Increasing Focus on Development of Cell-Based Therapeutics and Potential Biomarkers
Growing Prevalence and Incidence of Infectious and Chronic Diseases
Increasing Demand for Cell-Based Assays in Research and Development
Increasing Emphasis on Stem Cell Research
CHAPTER 4 CELL VIABILITY ASSAYS MARKET BY PRODUCT
Instruments
Automated Cell Counters
Flow Cytometers
Spectrophotometers
Cell Imaging and Analysis Systems
Consumables
Reagents
Assay Kits
Microplates
CHAPTER 5 MARKET BREAKDOWN BY CELL TYPE
Human Cells
Assays to Measure Viable Cells
Benefits of Protease Marker Assays
Advantages of ATP Assays
ATP Cell Viability Assay for Measuring Intrinsic Radio-Sensitivity in Cervical Cancer
Animal Cells
Advantages of Viability Assays for Animals
Microbial Cells
Cell Viability Assay to Determine the Cytotoxic Effects by Microbes in Water
Imaging Microbial Viability Assays
Imaging Biofilm Viability Assays
Bacterial Viability Assays for Flow Cytometry
Viability Detection of Foodborne Microbial Pathogens
Global Estimates of Foodborne Diseases
CHAPTER 6 MARKET BREAKDOWN BY APPLICATION
Clinical and Diagnostic Applications
Drug Discovery and Development
Stem Cell Research
Potential Benefits of Stem Cell Research
Basic Research
Other Applications (e.g., Toxicity Testing, Tissue Engineering)
Toxicity Testing
Tissue Engineering
CHAPTER 7 MARKET BREAKDOWN BY END USER
Academic and Research Institutions
Market Drivers
Pharmaceutical and Biotechnology Companies
UV-Spectrophotometers for Drug Stability Testing
Market Drivers
Hospitals and Diagnostic Laboratories
Cell Viability Assays
Assays and Their Substrates
Technological Advancements and Innovations
XTT Formazan Assay to Detect Cell Viability Inhibits HIV Type 1 Infection
Viability Assay to Identify Biologically-Relevant Malaria Transmission- Blocking Drugs
Assays for Diagnostic Tests for Malaria
Non-Blood Based Assays
Blood-Based Assays
Other End Users
Cancer Diagnosis and Prognosis
CHAPTER 8 MARKET BREAKDOWN BY REGION
North America
United States
Canada
Europe
United Kingdom
France
Germany
Spain
Rest of Europe
Asia-Pacific Region
China
Japan
India
Australia
Rest of Asia-Pacific
Rest of the World
Latin America
Middle East and Africa
CHAPTER 9 CELL VIABILITY ASSAYS MARKET INDUSTRY STRUCTURE
Raw Material Suppliers
Quality and Technology
Terms and Conditions
Cost-Effective Components
Manufacturers
Distributors
Raw Material Suppliers of Consumables
Quality
Terms and Conditions
Cost
Manufacturers of Consumables
Distributors of Consumables
End Users of Consumables
Innovation Within the Industry
Competitive Analysis
CHAPTER 10 COMPANY PROFILES
AAT BIOQUEST INC.
ABCAM
ABNOVA CORP.
ANASPEC INC.
BECTON, DICKINSON AND CO.
BIO-RAD LABORATORIES
BIOTEK INSTRUMENTS
BIOTIUM
BIOVISION INC.
CAYMAN CHEMICAL
CORNING INC.
CREATIVE BIOARRAY
DANAHER CORP.
DOJINDO MOLECULAR TECHNOLOGIES INC.
GE HEALTHCARE
INTELLICYT CORP.
MERCK KGAA
MESGEN
MOLECULAR DEVICES LLC
PERKINELMER
PROMEGA CORP.
R&D SYSTEMS INC.
TAKARA BIO INC.
THERMO FISHER SCIENTIFIC
VITASCIENTIFIC
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET OVERVIEW
Introduction
Market Potential
Market Size and Growth
Consumer Types and Product Success
Competitor Pricing
Regulatory Framework
United States
European Union
China
India
Japan
Australia
Brazil
Russia
Investment Analysis
Industry Growth Drivers
Increasing Focus on Development of Cell-Based Therapeutics and Potential Biomarkers
Growing Prevalence and Incidence of Infectious and Chronic Diseases
Increasing Demand for Cell-Based Assays in Research and Development
Increasing Emphasis on Stem Cell Research
CHAPTER 4 CELL VIABILITY ASSAYS MARKET BY PRODUCT
Instruments
Automated Cell Counters
Flow Cytometers
Spectrophotometers
Cell Imaging and Analysis Systems
Consumables
Reagents
Assay Kits
Microplates
CHAPTER 5 MARKET BREAKDOWN BY CELL TYPE
Human Cells
Assays to Measure Viable Cells
Benefits of Protease Marker Assays
Advantages of ATP Assays
ATP Cell Viability Assay for Measuring Intrinsic Radio-Sensitivity in Cervical Cancer
Animal Cells
Advantages of Viability Assays for Animals
Microbial Cells
Cell Viability Assay to Determine the Cytotoxic Effects by Microbes in Water
Imaging Microbial Viability Assays
Imaging Biofilm Viability Assays
Bacterial Viability Assays for Flow Cytometry
Viability Detection of Foodborne Microbial Pathogens
Global Estimates of Foodborne Diseases
CHAPTER 6 MARKET BREAKDOWN BY APPLICATION
Clinical and Diagnostic Applications
Drug Discovery and Development
Stem Cell Research
Potential Benefits of Stem Cell Research
Basic Research
Other Applications (e.g., Toxicity Testing, Tissue Engineering)
Toxicity Testing
Tissue Engineering
CHAPTER 7 MARKET BREAKDOWN BY END USER
Academic and Research Institutions
Market Drivers
Pharmaceutical and Biotechnology Companies
UV-Spectrophotometers for Drug Stability Testing
Market Drivers
Hospitals and Diagnostic Laboratories
Cell Viability Assays
Assays and Their Substrates
Technological Advancements and Innovations
XTT Formazan Assay to Detect Cell Viability Inhibits HIV Type 1 Infection
Viability Assay to Identify Biologically-Relevant Malaria Transmission- Blocking Drugs
Assays for Diagnostic Tests for Malaria
Non-Blood Based Assays
Blood-Based Assays
Other End Users
Cancer Diagnosis and Prognosis
CHAPTER 8 MARKET BREAKDOWN BY REGION
North America
United States
Canada
Europe
United Kingdom
France
Germany
Spain
Rest of Europe
Asia-Pacific Region
China
Japan
India
Australia
Rest of Asia-Pacific
Rest of the World
Latin America
Middle East and Africa
CHAPTER 9 CELL VIABILITY ASSAYS MARKET INDUSTRY STRUCTURE
Raw Material Suppliers
Quality and Technology
Terms and Conditions
Cost-Effective Components
Manufacturers
Distributors
Raw Material Suppliers of Consumables
Quality
Terms and Conditions
Cost
Manufacturers of Consumables
Distributors of Consumables
End Users of Consumables
Innovation Within the Industry
Competitive Analysis
CHAPTER 10 COMPANY PROFILES
AAT BIOQUEST INC.
ABCAM
ABNOVA CORP.
ANASPEC INC.
BECTON, DICKINSON AND CO.
BIO-RAD LABORATORIES
BIOTEK INSTRUMENTS
BIOTIUM
BIOVISION INC.
CAYMAN CHEMICAL
CORNING INC.
CREATIVE BIOARRAY
DANAHER CORP.
DOJINDO MOLECULAR TECHNOLOGIES INC.
GE HEALTHCARE
INTELLICYT CORP.
MERCK KGAA
MESGEN
MOLECULAR DEVICES LLC
PERKINELMER
PROMEGA CORP.
R&D SYSTEMS INC.
TAKARA BIO INC.
THERMO FISHER SCIENTIFIC
VITASCIENTIFIC
LIST OF TABLES
Summary Table: Global Cell Viability Assays Market, by Product, Through 2023
Table 1: Manufacturer and Distributor Product Pricing Comparison
Table 2: Examples of Requirements for UV-Visible Spectrophotometers
Table 3: Classes of Biologicals
Table 4: Cell Viability Assay Market: Key Recent Investments
Table 5: Recent Studies in Cell-Based Therapeutics
Table 6: NIH Funding Estimates for Various Conditions and Diseases, 2014-2019
Table 7: Leading Causes of Burden of Diseases around the World, 2004 and 2030
Table 8: Worldwide Cancer Incidence Rate, 2018
Table 9: Global Pharmaceutical R&D Spending, 2015-2022
Table 10: Pharmaceutical Research and Manufacturers of America Member Company R&D Expenditures, 2010 and 2016
Table 11: Investments in Stem Cell Research
Table 12: Global Cell Viability Assays Market, by Product, Through 2023
Table 13: Global Cell Viability Assays Instruments Market, by Type, Through 2023
Table 14: Global Cell Viability Assays Instruments Market, by Region, Through 2023
Table 15: Global Automated Cell Counters Market, by Region, Through 2023
Table 16: Global Flow Cytometers Market, by Region, Through 2023
Table 17: Feature-wise Comparison of Conventional Flow Cytometry and Imaging Flow Cytometry
Table 18: Key Analytical Parameters Measured by Flow Cytometers in Cell Viability Research
Table 19: Global Spectrophotometers Market, by Region, Through 2023
Table 20: Types of Spectrophotometers for Cell Viability Analysis
Table 21: Global Cell Imaging and Analysis Systems Market, by Region, Through 2023
Table 22: Global Cell Viability Assays Consumables Market, by Type, Through 2023
Table 23: Global Cell Viability Assays Consumables Market, by Region, Through 2023
Table 24: Global Reagents Market, by Region, Through 2023
Table 25: Library Screening of Small-Molecule Cancer Cells by Deploying Real-Time Cell Viability Assays
Table 26: List of Applications of Reagents for Drug Discovery
Table 27: List of Research Laboratories Using Reagents for Cell Viability Testing
Table 28: Global Assay Kits Market, by Region, Through 2023
Table 29: Global Assay kits Market, by Type, Through 2023
Table 30: MTT and XTT Kits Comparison
Table 31: Cost-effective Cell Viability Assays Through In Vitro Cell Screening and Cell Death Discrimination
Table 32: Procedure for Quantification of Cell Number Through MTT Assays
Table 33: Key Benefits and Features of XTT Assay Kits Over Radioactive Isotope Techniques
Table 34: List of Recently-Developed Chymotrypsin and Homogeneous Trypsin Protease Assays, 2017
Table 35: Global Microplates Market, by Region, Through 2023
Table 36: Funding for Various Projects in Life Sciences Research, 2017-2026
Table 37: Innovation Project Funds for BRAIN 2025 Priority Verticals
Table 38: Global Cell Viability Assays Market, by Cell Type, Through 2023
Table 39: Global Human Cells Market, by Region, Through 2023
Table 40: Rate of New Cancer Cases, 2018
Table 41: Global Deaths Due to Cancer, 2018
Table 42: Global Oncology Therapeutics Investment, 2011-2021
Table 43: Global Animal Cells Market, by Region, Through 2023
Table 44: Intracellular Assays to Measure Cellular Proliferation
Table 45: Global Microbial Cells Market, by Region, Through 2023
Table 46: Regional Foodborne Disease, 2016
Table 47: Global Cell Viability Assays Market, by Application, Through 2023
Table 48: Global Clinical and Diagnostic Applications Market, by Region, Through 2023
Table 49: Global Cancer Burden, 2012 and 2030
Table 50: Global Prevalence of Dementia, 2015-2050
Table 51: Global Pharmaceutical Market, 2015 and 2020
Table 52: Pharmaceutical Spending as a Percentage of Health Spending, by Country, 2016
Table 53: Global Biologics Spending, 2011 and 2016
Table 54: Global Drug Discovery and Development Market, by Region, Through 2023
Table 55: Global Total Pharmaceutical R&D Spending, 2015-2022
Table 56: Description of Government Support for Development of New Treatments in Organizations, by Country
Table 57: Global Stem Cell Research Market, by Region, Through 2023
Table 58: Application of Stem Cells in Regenerative Medicines
Table 59: NIH Spending on Stem Cell Research, 2014-2018 (Estimated)
Table 60: Growing Investment in Different Areas of Stem Cell-Based Research in the United States, 2016 and 2017
Table 61: Ongoing Clinical Diabetes-Based Stem Cell Research
Table 62: Ongoing Clinical Leukemia-Based Stem Cell Research
Table 63: Global Basic Research Market, by Region, Through 2023
Table 64: Top U.S. Academic Institutions Spending on R&D, 2018
Table 65: Global Others Application Market, by Region, Through 2023
Table 66: Funded Projects Supporting Tissue Engineering Solutions in Cancer Research
Table 67: Global Cell Viability Assays Market, by End User, Through 2023
Table 68: Global Academic and Research Institutions Market, by Region, Through 2023
Table 69: Current Cancer Research Grants, by Type, 2018
Table 70: Global Pharmaceutical and Biotechnology Companies Market, by Region, Through 2023
Table 71: Pharmaceutical R&D Spending by U.S., 2005-2015
Table 72: R&D Spending by Seven Pharma Giants in India, 2016
Table 73: Global Hospital and Diagnostic Laboratories in Cell Viability Assays Market, by Region, Through 2023
Table 74: Death Rates Due to Cancer, 2018
Table 75: People Infected with HIV, by Region, 2014-2016
Table 76: Malaria Deaths, by Region, 2014-2016
Table 77: Global Others End User Market, by Region, Through 2023
Table 78: Clinical Applications of Flow Cytometry
Table 79: Various Cancer Research Programs
Table 80: Selected Fluorescent Dyes for Specific Staining in Flow Cytometry Applications in Food Microbiology
Table 81: Global Cell Viability Assays Market, by Region, Through 2023
Table 82: North American Cell Viability Assays Market, by Country, Through 2023
Table 83: North American Cell Viability Assays Market, by Type, Through 2023
Table 84: North American Cell Viability Assays Market, by Application, Through 2023
Table 85: North American Cell Viability Assays Market, by End User, Through 2023
Table 86: North American Cell Viability Assays Market, by Product, Through 2023
Table 87: NIH Spending on Stem Cell Research, 2013-2016
Table 88: Healthcare Expenditures in Canada, 2015 and 2040
Table 89: Distribution of Annual Budget of Canadian Institutes of Health Research, 2016
Table 90: European Cell Viability Assays Market, by Country, Through 2023
Table 91: European Cell Viability Assays Market, by Product, Through 2023
Table 92: European Cell Viability Assays Market, by End User, Through 2023
Table 93: European Cell Viability Assays Market, by Type, Through 2023
Table 94: European Cell Viability Assays Market, by Application, Through 2023
Table 95: Estimated Number of People Living with Cancer, 2015 and 2020
Table 96: Deaths from and Number of People Living with Heart and Circulatory Diseases in the United Kingdom, 2016
Table 97: Government Funding for Drug-Based Research in France, 2010 and 2016
Table 98: Rising Number of Cancer Cases in Spain, 2012 and 2015
Table 99: Hospitals and Research Centers Participating in Clinical Trials on Cancer, 2004-2016
Table 100: Rising Prevalence of Breast Cancer in Norway, 2014 and 2015
Table 101: Asia-Pacific Cell Viability Assays Market, by Country, Through 2023
Table 102: Asia-Pacific Cell Viability Assays Market, by Product, Through 2023
Table 103: Asia-Pacific Cell Viability Assays Market, by Type, Through 2023
Table 104: Asia-Pacific Cell Viability Assays Market, by End User, Through 2023
Table 105: Asia-Pacific Cell Viability Assays Market, by Application, Through 2023
Table 106: Number of People with Cancer in China, 2010-2016
Table 107: Growth in Japanese Pharmaceuticals Industry, 2010-2015
Table 108: R&D Spending by Top Seven Pharmaceutical Companies in India, 2016
Table 109: Overall ROW R&D Expenditures, by Region, 2016 and 2017
Table 110: Rest of the World Cell Viability Assays Market, by Region, Through 2023
Table 111: Rest of the World Cell Viability Assays Market, by Application, Through 2023
Table 112: Rest of the World Cell Viability Assays Market, by Type, Through 2023
Table 113: Rest of the World Cell Viability Assays Market, by End User, Through 2023
Table 114: Rest of the World Cell Viability Assays Market, by Product, Through 2023
Table 115: Deaths in Brazil Due to Cancer, by Type, 2010 and 2016
Table 116: Prevalence of Cancer in Brazil, by Type, 2010 and 2016
Table 117: Capital Raised by Israeli High-Tech Companies, 2013-2017
Table 118: Raw Material/Part Manufacturers
Table 119: Manufacturers Operating in the Cell Assays Market
Table 120: Distributors Operating in the Cell Assays Market
Table 121: Raw Material/Part Manufacturers
Table 122: Manufacturers Operating in the Cell Assays Market
Table 123: Distribution of Cell Assays Studies Globally, 2018
Table 124: Use of Competitive Strategies in the Global Cell Viability Assay Market, 2015 and 2018
Table 125: AAT Bioquest Inc.: Product Portfolio
Table 126: ABCAM: Product Portfolio
Table 127: ABCAM: Recent Developments
Table 128: Abnova: Product Portfolio
Table 129: Abnova: Recent Developments, 2015-2018
Table 130: AnaSpec Inc.: Product Portfolio
Table 131: AnaSpec Inc.: Recent Developments
Table 132: Becton, Dickinson and Co.: Product Portfolio
Table 133: Becton, Dickinson and Co.: Recent Developments
Table 134: Bio-Rad Laboratories: Product Portfolio
Table 135: Bio-Rad Laboratories: Recent Developments
Table 136: BioTek Instruments Inc.: Product Portfolio
Table 137: BioTek Instruments Inc.: Developments, April 2016-October 2018
Table 138: Biotium: Product Portfolio
Table 139: BioVision Inc.: Product Portfolio
Table 140: Cayman Chemical: Product Portfolio
Table 141: Cayman Chemical: Recent Developments
Table 142: Corning Inc.: Product Portfolio
Table 143: Creative Bioarray: Product Portfolio
Table 144: Danaher Corp.: Product Portfolio
Table 145: Danaher Corp.: Recent Developments
Table 146: Dojindo Molecular Technologies Inc.: Product Portfolio
Table 147: GE Healthcare: Product Portfolio
Table 148: Intellicyt Corp.: Product Portfolio
Table 149: Intellicyt Corp.: Recent Developments
Table 150: Merck KGAA: Product Portfolio
Table 151: Merck KGAA: Recent Developments
Table 152: MesGen: Product Portfolio
Table 153: Molecular Devices LLC: Product Portfolio
Table 154: Molecular Devices LLC: Recent Developments
Table 155: PerkinElmer Inc.: Product Portfolio
Table 156: Promega Corp.: Product Portfolio
Table 157: R&D Systems Inc.: Product Portfolio
Table 158: Takara Bio Inc.: Product Portfolio
Table 159: Takara Bio Inc.: Recent Developments
Table 160: Thermo Fisher Scientific: Product Portfolio
Table 161: VitaScientific: Product Portfolio
Summary Table: Global Cell Viability Assays Market, by Product, Through 2023
Table 1: Manufacturer and Distributor Product Pricing Comparison
Table 2: Examples of Requirements for UV-Visible Spectrophotometers
Table 3: Classes of Biologicals
Table 4: Cell Viability Assay Market: Key Recent Investments
Table 5: Recent Studies in Cell-Based Therapeutics
Table 6: NIH Funding Estimates for Various Conditions and Diseases, 2014-2019
Table 7: Leading Causes of Burden of Diseases around the World, 2004 and 2030
Table 8: Worldwide Cancer Incidence Rate, 2018
Table 9: Global Pharmaceutical R&D Spending, 2015-2022
Table 10: Pharmaceutical Research and Manufacturers of America Member Company R&D Expenditures, 2010 and 2016
Table 11: Investments in Stem Cell Research
Table 12: Global Cell Viability Assays Market, by Product, Through 2023
Table 13: Global Cell Viability Assays Instruments Market, by Type, Through 2023
Table 14: Global Cell Viability Assays Instruments Market, by Region, Through 2023
Table 15: Global Automated Cell Counters Market, by Region, Through 2023
Table 16: Global Flow Cytometers Market, by Region, Through 2023
Table 17: Feature-wise Comparison of Conventional Flow Cytometry and Imaging Flow Cytometry
Table 18: Key Analytical Parameters Measured by Flow Cytometers in Cell Viability Research
Table 19: Global Spectrophotometers Market, by Region, Through 2023
Table 20: Types of Spectrophotometers for Cell Viability Analysis
Table 21: Global Cell Imaging and Analysis Systems Market, by Region, Through 2023
Table 22: Global Cell Viability Assays Consumables Market, by Type, Through 2023
Table 23: Global Cell Viability Assays Consumables Market, by Region, Through 2023
Table 24: Global Reagents Market, by Region, Through 2023
Table 25: Library Screening of Small-Molecule Cancer Cells by Deploying Real-Time Cell Viability Assays
Table 26: List of Applications of Reagents for Drug Discovery
Table 27: List of Research Laboratories Using Reagents for Cell Viability Testing
Table 28: Global Assay Kits Market, by Region, Through 2023
Table 29: Global Assay kits Market, by Type, Through 2023
Table 30: MTT and XTT Kits Comparison
Table 31: Cost-effective Cell Viability Assays Through In Vitro Cell Screening and Cell Death Discrimination
Table 32: Procedure for Quantification of Cell Number Through MTT Assays
Table 33: Key Benefits and Features of XTT Assay Kits Over Radioactive Isotope Techniques
Table 34: List of Recently-Developed Chymotrypsin and Homogeneous Trypsin Protease Assays, 2017
Table 35: Global Microplates Market, by Region, Through 2023
Table 36: Funding for Various Projects in Life Sciences Research, 2017-2026
Table 37: Innovation Project Funds for BRAIN 2025 Priority Verticals
Table 38: Global Cell Viability Assays Market, by Cell Type, Through 2023
Table 39: Global Human Cells Market, by Region, Through 2023
Table 40: Rate of New Cancer Cases, 2018
Table 41: Global Deaths Due to Cancer, 2018
Table 42: Global Oncology Therapeutics Investment, 2011-2021
Table 43: Global Animal Cells Market, by Region, Through 2023
Table 44: Intracellular Assays to Measure Cellular Proliferation
Table 45: Global Microbial Cells Market, by Region, Through 2023
Table 46: Regional Foodborne Disease, 2016
Table 47: Global Cell Viability Assays Market, by Application, Through 2023
Table 48: Global Clinical and Diagnostic Applications Market, by Region, Through 2023
Table 49: Global Cancer Burden, 2012 and 2030
Table 50: Global Prevalence of Dementia, 2015-2050
Table 51: Global Pharmaceutical Market, 2015 and 2020
Table 52: Pharmaceutical Spending as a Percentage of Health Spending, by Country, 2016
Table 53: Global Biologics Spending, 2011 and 2016
Table 54: Global Drug Discovery and Development Market, by Region, Through 2023
Table 55: Global Total Pharmaceutical R&D Spending, 2015-2022
Table 56: Description of Government Support for Development of New Treatments in Organizations, by Country
Table 57: Global Stem Cell Research Market, by Region, Through 2023
Table 58: Application of Stem Cells in Regenerative Medicines
Table 59: NIH Spending on Stem Cell Research, 2014-2018 (Estimated)
Table 60: Growing Investment in Different Areas of Stem Cell-Based Research in the United States, 2016 and 2017
Table 61: Ongoing Clinical Diabetes-Based Stem Cell Research
Table 62: Ongoing Clinical Leukemia-Based Stem Cell Research
Table 63: Global Basic Research Market, by Region, Through 2023
Table 64: Top U.S. Academic Institutions Spending on R&D, 2018
Table 65: Global Others Application Market, by Region, Through 2023
Table 66: Funded Projects Supporting Tissue Engineering Solutions in Cancer Research
Table 67: Global Cell Viability Assays Market, by End User, Through 2023
Table 68: Global Academic and Research Institutions Market, by Region, Through 2023
Table 69: Current Cancer Research Grants, by Type, 2018
Table 70: Global Pharmaceutical and Biotechnology Companies Market, by Region, Through 2023
Table 71: Pharmaceutical R&D Spending by U.S., 2005-2015
Table 72: R&D Spending by Seven Pharma Giants in India, 2016
Table 73: Global Hospital and Diagnostic Laboratories in Cell Viability Assays Market, by Region, Through 2023
Table 74: Death Rates Due to Cancer, 2018
Table 75: People Infected with HIV, by Region, 2014-2016
Table 76: Malaria Deaths, by Region, 2014-2016
Table 77: Global Others End User Market, by Region, Through 2023
Table 78: Clinical Applications of Flow Cytometry
Table 79: Various Cancer Research Programs
Table 80: Selected Fluorescent Dyes for Specific Staining in Flow Cytometry Applications in Food Microbiology
Table 81: Global Cell Viability Assays Market, by Region, Through 2023
Table 82: North American Cell Viability Assays Market, by Country, Through 2023
Table 83: North American Cell Viability Assays Market, by Type, Through 2023
Table 84: North American Cell Viability Assays Market, by Application, Through 2023
Table 85: North American Cell Viability Assays Market, by End User, Through 2023
Table 86: North American Cell Viability Assays Market, by Product, Through 2023
Table 87: NIH Spending on Stem Cell Research, 2013-2016
Table 88: Healthcare Expenditures in Canada, 2015 and 2040
Table 89: Distribution of Annual Budget of Canadian Institutes of Health Research, 2016
Table 90: European Cell Viability Assays Market, by Country, Through 2023
Table 91: European Cell Viability Assays Market, by Product, Through 2023
Table 92: European Cell Viability Assays Market, by End User, Through 2023
Table 93: European Cell Viability Assays Market, by Type, Through 2023
Table 94: European Cell Viability Assays Market, by Application, Through 2023
Table 95: Estimated Number of People Living with Cancer, 2015 and 2020
Table 96: Deaths from and Number of People Living with Heart and Circulatory Diseases in the United Kingdom, 2016
Table 97: Government Funding for Drug-Based Research in France, 2010 and 2016
Table 98: Rising Number of Cancer Cases in Spain, 2012 and 2015
Table 99: Hospitals and Research Centers Participating in Clinical Trials on Cancer, 2004-2016
Table 100: Rising Prevalence of Breast Cancer in Norway, 2014 and 2015
Table 101: Asia-Pacific Cell Viability Assays Market, by Country, Through 2023
Table 102: Asia-Pacific Cell Viability Assays Market, by Product, Through 2023
Table 103: Asia-Pacific Cell Viability Assays Market, by Type, Through 2023
Table 104: Asia-Pacific Cell Viability Assays Market, by End User, Through 2023
Table 105: Asia-Pacific Cell Viability Assays Market, by Application, Through 2023
Table 106: Number of People with Cancer in China, 2010-2016
Table 107: Growth in Japanese Pharmaceuticals Industry, 2010-2015
Table 108: R&D Spending by Top Seven Pharmaceutical Companies in India, 2016
Table 109: Overall ROW R&D Expenditures, by Region, 2016 and 2017
Table 110: Rest of the World Cell Viability Assays Market, by Region, Through 2023
Table 111: Rest of the World Cell Viability Assays Market, by Application, Through 2023
Table 112: Rest of the World Cell Viability Assays Market, by Type, Through 2023
Table 113: Rest of the World Cell Viability Assays Market, by End User, Through 2023
Table 114: Rest of the World Cell Viability Assays Market, by Product, Through 2023
Table 115: Deaths in Brazil Due to Cancer, by Type, 2010 and 2016
Table 116: Prevalence of Cancer in Brazil, by Type, 2010 and 2016
Table 117: Capital Raised by Israeli High-Tech Companies, 2013-2017
Table 118: Raw Material/Part Manufacturers
Table 119: Manufacturers Operating in the Cell Assays Market
Table 120: Distributors Operating in the Cell Assays Market
Table 121: Raw Material/Part Manufacturers
Table 122: Manufacturers Operating in the Cell Assays Market
Table 123: Distribution of Cell Assays Studies Globally, 2018
Table 124: Use of Competitive Strategies in the Global Cell Viability Assay Market, 2015 and 2018
Table 125: AAT Bioquest Inc.: Product Portfolio
Table 126: ABCAM: Product Portfolio
Table 127: ABCAM: Recent Developments
Table 128: Abnova: Product Portfolio
Table 129: Abnova: Recent Developments, 2015-2018
Table 130: AnaSpec Inc.: Product Portfolio
Table 131: AnaSpec Inc.: Recent Developments
Table 132: Becton, Dickinson and Co.: Product Portfolio
Table 133: Becton, Dickinson and Co.: Recent Developments
Table 134: Bio-Rad Laboratories: Product Portfolio
Table 135: Bio-Rad Laboratories: Recent Developments
Table 136: BioTek Instruments Inc.: Product Portfolio
Table 137: BioTek Instruments Inc.: Developments, April 2016-October 2018
Table 138: Biotium: Product Portfolio
Table 139: BioVision Inc.: Product Portfolio
Table 140: Cayman Chemical: Product Portfolio
Table 141: Cayman Chemical: Recent Developments
Table 142: Corning Inc.: Product Portfolio
Table 143: Creative Bioarray: Product Portfolio
Table 144: Danaher Corp.: Product Portfolio
Table 145: Danaher Corp.: Recent Developments
Table 146: Dojindo Molecular Technologies Inc.: Product Portfolio
Table 147: GE Healthcare: Product Portfolio
Table 148: Intellicyt Corp.: Product Portfolio
Table 149: Intellicyt Corp.: Recent Developments
Table 150: Merck KGAA: Product Portfolio
Table 151: Merck KGAA: Recent Developments
Table 152: MesGen: Product Portfolio
Table 153: Molecular Devices LLC: Product Portfolio
Table 154: Molecular Devices LLC: Recent Developments
Table 155: PerkinElmer Inc.: Product Portfolio
Table 156: Promega Corp.: Product Portfolio
Table 157: R&D Systems Inc.: Product Portfolio
Table 158: Takara Bio Inc.: Product Portfolio
Table 159: Takara Bio Inc.: Recent Developments
Table 160: Thermo Fisher Scientific: Product Portfolio
Table 161: VitaScientific: Product Portfolio
LIST OF FIGURES
Summary Figure: Global Cell Viability Assays Market, by Product, 2017-2023
Figure 1: Research Funding for Biological Science Research Studies, 2017
Figure 2: Global Tissue Engineering and Cell Therapy Market Growth, 2009-2018
Figure 3: Global Projections for Deaths from the Top Three Chronic Diseases, 2005-2030
Figure 4: Worldwide Cancer Incidence Rate, by Type, 2018
Figure 5: Global Pharmaceutical R&D Spending, 2015-2022
Figure 6: Pharmaceutical Research and Manufacturers of America Member Company R&D Expenditures, 2010 and 2016
Figure 7: Cell Viability Assays Market, by Product
Figure 8: Types of Automated Cell Counters
Figure 9: dPCR used for Viability of Genetically Modified Organisms (GMOs)
Figure 10: Types of Consumables in the Cell Viability Assays Market
Figure 11: Classification of Assay kits
Figure 12: Conversion of Resazurin to Resorufin to Determine Cell Viability
Figure 13: Protease Activity Assays
Figure 14: Global Deaths Due to Cancer, 2018
Figure 15: Global Oncology Therapeutics Investment, 2011-2021
Figure 16: Approaches for Bacterial Viability Assessment
Figure 17: PMA-qPCR Assay and PMA treatment
Figure 18: Major Growth Factors of Global Cell Viability Assays Market, by Application
Figure 19: Cell Viability Assay Products Used in Clinical and Diagnostics Application
Figure 20: Global Cancer Burden, 2012 and 2030
Figure 21: Global Prevalence of Dementia, 2015-2050
Figure 22: Evaluation of Cell Viability Using Flow Cytometry Technique
Figure 23: Global Pharmaceutical Market, 2015 and 2020
Figure 24: Pharmaceutical Spending as a Percentage of Health Spending, 2016
Figure 25: Global Biologics Spending, 2011 and 2016
Figure 26: Global Total of Pharmaceutical R&D Spending, 2015-2022
Figure 27: Classification of Stem Cells
Figure 28: NIH Spending on Stem Cell Research, 2014-2018 (Estimated)
Figure 29: Growing Investment in Different Stem Cell-Based Research in the United States, 2016 and 2017
Figure 30: Rise in R&D Expenditures in 2018 Compared with 2017
Figure 31: Global Spending on Life Sciences R&D, 2015-2018
Figure 32: Top R&D Spending Nations in Europe, 2017 and 2018
Figure 33: Investment in Research and Innovation Through European Commission Framework Programs, 1984-2027
Figure 34: Number of Research Grants Received by European Countries, 2018
Figure 35: R&D Expenditures of the Top 20 Countries in Asia, 2017 and 2018
Figure 36: Cell Viability Assays End Users
Figure 37: Major Factors Driving Growth of the Cell Viability Assays Market
Figure 38: Generalized Scheme Representing an In Vitro Cytotoxicity Assay Protocol
Figure 39: Methods of Cell Viability Counting Used in Research Institutions
Figure 40: Usage of Flow Cytometry in the Drug Discovery and Development Process
Figure 41: U.S. Pharmaceutical R&D Spending, 2005-2015
Figure 42: R&D Spending by India’s Seven Largest Pharma Companies, 2016
Figure 43: Death Rates Due to Cancer, 2018
Figure 44: People Infected with HIV, by Region, 2014-2016
Figure 45: Malaria Deaths, by Region, 2014-2016
Figure 46: NIH Spending on Stem Cell Research, 2013-2016
Figure 47: Healthcare Expenditures in Canada, 2015 and 2040
Figure 48: Distribution of Annual Budget of Canadian Institute of Health Research, 2016
Figure 49: Estimated Number of People Living with Cancer in the U.K., 2015 vs. 2020
Figure 50: Government Funding for Drug-Based Research in France, 2010 and 2016
Figure 51: Rising Number of Cancer Cases in Spain, 2012 and 2015
Figure 52: Hospitals and Research Centers Participating in Clinical Trials on Cancer, 2004-2016
Figure 53: Rising Prevalence of Breast Cancer in Norway, 2014 and 2015
Figure 54: Number of People with Cancer in China, 2010-2016
Figure 55: Japanese Pharmaceuticals Industry, 2010-2015
Figure 56: R&D Spending by Top Seven Pharmaceutical Companies in India, 2018
Figure 57: Overall ROW R&D Expenditures, by Region, 2016 and 2017
Figure 58: Deaths in Brazil Due to Cancer, 2010 and 2016
Figure 59: Capital Raised by Israeli High-Tech Companies, 2013-2017
Figure 60: Industry Structure of Instruments Used in Cell Viability Assays Market
Figure 61: Industry Structure of Consumables Used in the Cell Viability Assays Market
Figure 62: Distribution of Cell Assays Studies Globally, 2018
Figure 63: Competitive Strategies Used in the Global Cell Viability Assay Market, 2015 and 2018
Summary Figure: Global Cell Viability Assays Market, by Product, 2017-2023
Figure 1: Research Funding for Biological Science Research Studies, 2017
Figure 2: Global Tissue Engineering and Cell Therapy Market Growth, 2009-2018
Figure 3: Global Projections for Deaths from the Top Three Chronic Diseases, 2005-2030
Figure 4: Worldwide Cancer Incidence Rate, by Type, 2018
Figure 5: Global Pharmaceutical R&D Spending, 2015-2022
Figure 6: Pharmaceutical Research and Manufacturers of America Member Company R&D Expenditures, 2010 and 2016
Figure 7: Cell Viability Assays Market, by Product
Figure 8: Types of Automated Cell Counters
Figure 9: dPCR used for Viability of Genetically Modified Organisms (GMOs)
Figure 10: Types of Consumables in the Cell Viability Assays Market
Figure 11: Classification of Assay kits
Figure 12: Conversion of Resazurin to Resorufin to Determine Cell Viability
Figure 13: Protease Activity Assays
Figure 14: Global Deaths Due to Cancer, 2018
Figure 15: Global Oncology Therapeutics Investment, 2011-2021
Figure 16: Approaches for Bacterial Viability Assessment
Figure 17: PMA-qPCR Assay and PMA treatment
Figure 18: Major Growth Factors of Global Cell Viability Assays Market, by Application
Figure 19: Cell Viability Assay Products Used in Clinical and Diagnostics Application
Figure 20: Global Cancer Burden, 2012 and 2030
Figure 21: Global Prevalence of Dementia, 2015-2050
Figure 22: Evaluation of Cell Viability Using Flow Cytometry Technique
Figure 23: Global Pharmaceutical Market, 2015 and 2020
Figure 24: Pharmaceutical Spending as a Percentage of Health Spending, 2016
Figure 25: Global Biologics Spending, 2011 and 2016
Figure 26: Global Total of Pharmaceutical R&D Spending, 2015-2022
Figure 27: Classification of Stem Cells
Figure 28: NIH Spending on Stem Cell Research, 2014-2018 (Estimated)
Figure 29: Growing Investment in Different Stem Cell-Based Research in the United States, 2016 and 2017
Figure 30: Rise in R&D Expenditures in 2018 Compared with 2017
Figure 31: Global Spending on Life Sciences R&D, 2015-2018
Figure 32: Top R&D Spending Nations in Europe, 2017 and 2018
Figure 33: Investment in Research and Innovation Through European Commission Framework Programs, 1984-2027
Figure 34: Number of Research Grants Received by European Countries, 2018
Figure 35: R&D Expenditures of the Top 20 Countries in Asia, 2017 and 2018
Figure 36: Cell Viability Assays End Users
Figure 37: Major Factors Driving Growth of the Cell Viability Assays Market
Figure 38: Generalized Scheme Representing an In Vitro Cytotoxicity Assay Protocol
Figure 39: Methods of Cell Viability Counting Used in Research Institutions
Figure 40: Usage of Flow Cytometry in the Drug Discovery and Development Process
Figure 41: U.S. Pharmaceutical R&D Spending, 2005-2015
Figure 42: R&D Spending by India’s Seven Largest Pharma Companies, 2016
Figure 43: Death Rates Due to Cancer, 2018
Figure 44: People Infected with HIV, by Region, 2014-2016
Figure 45: Malaria Deaths, by Region, 2014-2016
Figure 46: NIH Spending on Stem Cell Research, 2013-2016
Figure 47: Healthcare Expenditures in Canada, 2015 and 2040
Figure 48: Distribution of Annual Budget of Canadian Institute of Health Research, 2016
Figure 49: Estimated Number of People Living with Cancer in the U.K., 2015 vs. 2020
Figure 50: Government Funding for Drug-Based Research in France, 2010 and 2016
Figure 51: Rising Number of Cancer Cases in Spain, 2012 and 2015
Figure 52: Hospitals and Research Centers Participating in Clinical Trials on Cancer, 2004-2016
Figure 53: Rising Prevalence of Breast Cancer in Norway, 2014 and 2015
Figure 54: Number of People with Cancer in China, 2010-2016
Figure 55: Japanese Pharmaceuticals Industry, 2010-2015
Figure 56: R&D Spending by Top Seven Pharmaceutical Companies in India, 2018
Figure 57: Overall ROW R&D Expenditures, by Region, 2016 and 2017
Figure 58: Deaths in Brazil Due to Cancer, 2010 and 2016
Figure 59: Capital Raised by Israeli High-Tech Companies, 2013-2017
Figure 60: Industry Structure of Instruments Used in Cell Viability Assays Market
Figure 61: Industry Structure of Consumables Used in the Cell Viability Assays Market
Figure 62: Distribution of Cell Assays Studies Globally, 2018
Figure 63: Competitive Strategies Used in the Global Cell Viability Assay Market, 2015 and 2018
